Liquidia Corp

Liquidia Corp’s CEO Jeff Rogers’ disciplined 10b‑5‑1 sell‑off shows liquidity management, not panic—while the company’s nanoparticle platform and LiNP‑101 breakthrough therapy remain strong prospects for investors and clinicians.

Liquidia Corp. insider sale: Stephen Bloch sold 75,801 shares amid bullish momentum, yet analysts say the routine trade won’t dampen the company’s high‑growth outlook.

Liquidia Corp’s CEO sales of 125,000 shares in May 2026: how Rule 10b‑5 plan trades affect investor confidence, R&D funding, and the biotech pipeline for YUTREPIA.

CEO Roger Jeffs’ small, plan‑driven sales show confidence while supporting Liquidia’s growth in PRINT® tech and value‑based healthcare.
Investors can expect stability and long‑term potential.

Liquidia Corp insider sales raise questions about its biotech strategy and future value—explore the implications for investors and the nanoparticle market.

Liquidia insiders, led by HR chief Sarah Krepp, are buying stock under 10b‑5‑1 plans, signaling confidence in the company’s nanoparticle platform and upcoming clinical milestones. This insider activity, alongside rising social‑media buzz and an 8.4%…

Liquidia insider purchase shows confidence in its micro‑ and nanoparticle platform amid a 24% price drop – watch pipeline milestones, reimbursement and growth prospects.

Liquidia Corp’s Q1 insider sales reveal a tax‑driven strategy amid rising oncology earnings, with executives buying shares while managing risk and positioning for value‑based care success.

Liquidia Corp’s insider buying shows management confidence, aligning with a recent earnings beat and a promising nanoparticle platform—an optimistic signal for investors.